Gilead Sciences (MIL:1GILD) 3-Year Book Growth Rate : 8.10% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Gilead Sciences 3-Year Book Growth Rate?

Gilead Sciences's Book Value per Share for the quarter that ended in Dec. 2023 was €16.80.

During the past 12 months, Gilead Sciences's average Book Value per Share Growth Rate was 7.60% per year. During the past 3 years, the average Book Value per Share Growth Rate was 8.10% per year. During the past 5 years, the average Book Value per Share Growth Rate was 1.40% per year. During the past 10 years, the average Book Value per Share Growth Rate was 7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Gilead Sciences was 65.90% per year. The lowest was -13.50% per year. And the median was 19.60% per year.

Competitive Comparison of Gilead Sciences's 3-Year Book Growth Rate

For the Drug Manufacturers - General subindustry, Gilead Sciences's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's 3-Year Book Growth Rate falls into.

Gilead Sciences 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Gilead Sciences (MIL:1GILD) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Gilead Sciences 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (MIL:1GILD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (MIL:1GILD) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GISd:UK 0QYQ:UK GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (MIL:1GILD) Headlines

No Headlines